Commentary - (2025) Volume 12, Issue 6
Received: 01-Dec-2025, Manuscript No. jpd-26-183950;
Editor assigned: 03-Dec-2025, Pre QC No. P-183950;
Reviewed: 17-Dec-2025, QC No. Q-183950;
Revised: 22-Dec-2025, Manuscript No. R-183950;
Published:
29-Dec-2025
, DOI: 10.37421/2684-4281.2025.12.554
Citation: Horvath, Renata S.. ”Skin Side Effects of Cancer Therapies.” J Dermatol Dis 12 (2025):554.
Copyright: © 2025 Horvath S. Renata This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Chemotherapy and radiotherapy, indispensable pillars in modern oncological treatment, are frequently associated with a spectrum of cutaneous adverse effects that necessitate careful management and patient monitoring. These dermatologic manifestations can range from mild to severe, significantly impacting a patient's quality of life and potentially leading to treatment interruptions [1].
Radiation-induced skin reactions represent a common and often challenging aspect of radiotherapy. Acute reactions, such as erythema and desquamation, typically appear during or shortly after treatment, while chronic changes like fibrosis and telangiectasias can persist long-term [2].
Beyond traditional modalities, novel therapeutic approaches such as targeted therapies and immunotherapies, while revolutionizing cancer care, introduce a unique set of dermatologic toxicities. Immune-related adverse events (irAEs) manifest in diverse skin conditions, requiring specialized management strategies [3].
Chemotherapy is also known to induce various systemic side effects, including significant changes to the nails. Onychodystrophy, characterized by conditions like onycholysis and Beau's lines, can cause pain and increase the risk of infection, underscoring the importance of supportive care [4].
Two particularly bothersome and frequent side effects encountered across various cancer therapies are xerosis and pruritus. Effective management of dry skin and itching relies on a comprehensive approach involving emollients, antipruritic agents, and patient education on environmental modifications [5].
A peculiar phenomenon known as radiation recall highlights the enduring vulnerability of irradiated skin. This reaction, where previously treated skin flares up in response to subsequent systemic treatments, emphasizes the complex interplay between radiation and systemic therapies [6].
Compromised skin integrity, a common consequence of cancer treatments, predisposes patients to infections. Bacterial and fungal skin infections can arise, necessitating prompt recognition and treatment to prevent further complications and systemic spread [7].
Certain chemotherapeutic agents can also render the skin more susceptible to light. Phototoxicity, an exaggerated response to UV radiation, can manifest as severe sunburns and photosensitive rashes, requiring strict sun protection measures [8].
Alterations in skin pigmentation, including hyperpigmentation and hypopigmentation, are frequently observed following chemotherapy and radiotherapy. These pigmentary changes, stemming from melanocyte dysfunction, can cause significant aesthetic concerns and distress for patients [9].
Finally, alopecia, or hair loss, remains a prominent and psychologically impactful side effect of numerous chemotherapy regimens. While localized hair loss can result from radiotherapy, systemic chemotherapy often leads to diffuse hair thinning or complete baldness, prompting the exploration of preventative strategies like scalp cooling [10].
The extensive literature on cancer therapeutics consistently reports a wide array of cutaneous adverse effects stemming from both conventional and novel treatment modalities. Chemotherapy and radiotherapy, while critical for disease control, can induce a spectrum of skin reactions, ranging from xerosis and pruritus to more severe forms of dermatitis, ulceration, and even secondary malignancies [1].
Radiotherapy, a cornerstone of cancer treatment, is particularly associated with a well-defined set of skin reactions. Acute radiation dermatitis, characterized by erythema, dry or moist desquamation, and pain, typically manifests during the course of treatment. The cumulative effects of radiation can also lead to chronic changes, including telangiectasias, fibrosis, and atrophy, necessitating long-term dermatological follow-up [2].
In parallel, the advent of targeted therapies and immunotherapies has expanded the landscape of cancer treatment but has also introduced unique dermatologic toxicities. Immune-related adverse events (irAEs) can present with a variety of skin manifestations, including maculopapular rashes, pruritus, and less commonly, more severe dermatoses, demanding vigilant monitoring and tailored management [3].
Chemotherapy's impact extends to nail health, with chemotherapy-induced nail changes being a common concern. Conditions such as onycholysis and Beau's lines can impair function and lead to secondary infections, highlighting the need for preventive and supportive measures to maintain nail integrity [4].
Xerosis and pruritus are frequently encountered side effects across different cancer therapies. The management of these conditions is multifactorial, involving the consistent application of emollients for dry skin and the judicious use of antipruritic agents, alongside patient education aimed at minimizing environmental triggers and irritants [5].
The phenomenon of radiation recall, where irradiated skin reacts adversely to systemic medications, underscores the lasting sensitivity of tissues subjected to radiation therapy. This exacerbation of previous radiation dermatitis serves as a critical reminder of potential drug-induced reactions in previously treated areas [6].
Skin infections, both bacterial and fungal, pose a significant risk in cancer patients due to compromised skin barrier function and immunosuppression. Proactive strategies focusing on skin integrity and prompt management of any excoriations or lesions are crucial to prevent the development and spread of infections [7].
Phototoxicity, an exaggerated sensitivity to sunlight and UV radiation, can be induced or exacerbated by certain chemotherapeutic agents. This reaction, often presenting as severe sunburn-like symptoms, mandates strict adherence to sun avoidance and the consistent use of broad-spectrum sunscreens [8].
Pigmentary changes, including both hyperpigmentation and hypopigmentation, are common dermatologic sequelae of chemotherapy and radiotherapy. These alterations, arising from disruptions in melanocyte function, can be aesthetically significant and a source of patient distress, often requiring long-term supportive care [9].
Alopecia, a distressing side effect of many chemotherapy regimens, involves the loss of hair. Radiotherapy can also lead to localized hair loss in the treated area. The effectiveness of interventions like scalp cooling in mitigating chemotherapy-induced alopecia is an active area of research and clinical application, with hair regrowth typically observed post-treatment [10].
Cancer therapies, including chemotherapy and radiotherapy, frequently cause a range of cutaneous adverse effects. These can manifest as skin dryness, itching, radiation dermatitis, nail changes, pigment alterations, and hair loss. Novel treatments like targeted therapies and immunotherapies also present unique dermatologic toxicities, such as immune-related adverse events. Management strategies are crucial for mitigating these side effects and preserving patient quality of life. This includes supportive care, topical agents, and sometimes dose adjustments. Specific concerns like radiation recall and increased susceptibility to skin infections also require attention. Patient education on sun protection and environmental modifications is also vital for managing these treatment-related complications.
None
None
Journal of Dermatology and Dermatologic Diseases received 4 citations as per Google Scholar report
